Research
Hormonal
GLP-1 analogues (e.g., liraglutide, exenatide) show promise in animal models for reducing amyloid plaques, tau phosphorylation, and improving cognition, but human clinical trials have shown mixed or disappointing results so far.
GLP-1 drugs (like Ozempic/Wegovy) are being studied for Alzheimer's. While they work well in mice, human trials have not yet confirmed they improve memory or reduce brain plaques. Do not expect them to cure AD yet, but maintaining metabolic health with these drugs may still offer some neuroprotective benefits.
ModerateQualifiesMEDIUM confidence
Although the first small clinical trial of liraglutide in AD patients did not lead to any improvement in cognition or changes in Aβ deposition... a recent clinical trial of exenatide in Parkinson’s disease patients demonstrated clinically relevant improvements in motor and cognitive measures.
Why this rating
Strong animal data, but early/mixed human trial data.
Source
Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome
Bhumsoo Kim et al. · Experimental & Molecular Medicine · 2015
DOI 10.1038/emm.2015.3
narrative_reviewCited 341×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance (IR) is the primary mechanistic link connecting Metabolic Syndrome (MetS) to increased risk of Alzheimer's Disease (AD) and cognitive impairment, driven by impaired PI3K-Akt signaling, increased amyloid-beta (Aβ) production, and tau hyperphosphorylation.Good
- Intranasal insulin administration improves memory and cognitive function in early Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) patients, particularly those who are ApoE-ε4 negative.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →